[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Generics in the United States

August 2020 | 41 pages | ID: GA48E99C3C1EN
MarketLine

US$ 350.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Generics in the United States

SUMMARY

Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY HIGHLIGHTS
  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The US generics market had total revenues of $108.9bn in 2019, representing a compound annual growth rate (CAGR) of 3.8% between 2015 and 2019.
  • Market consumption volume increased with a CAGR of 0.8% between 2015 and 2019, to reach a total of 92.7% in 2019.
  • With the lack of a national healthcare system in the US, the government cannot always secure low prices for medication.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United States
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume
REASONS TO BUY
  • What was the size of the United States generics market by value in 2019?
  • What will be the size of the United States generics market in 2024?
  • What factors are affecting the strength of competition in the United States generics market?
  • How has the market performed over the last five years?
  • How large is the United States’s generics market in relation to its regional counterparts?
1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Pfizer Inc.

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

LIST OF TABLES

Table 1: United States generics market value: $ billion, 2015-19
Table 2: United States generics market volume: % of total pharma, 2015-19
Table 3: United States generics market geography segmentation: $ billion, 2019
Table 4: United States generics market value forecast: $ billion, 2019-24
Table 5: United States generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: United States size of population (million), 2015-19
Table 17: United States gdp (constant 2005 prices, $ billion), 2015-19
Table 18: United States gdp (current prices, $ billion), 2015-19
Table 19: United States inflation, 2015-19
Table 20: United States consumer price index (absolute), 2015-19
Table 21: United States exchange rate, 2015-19

LIST OF FIGURES

Figure 1: United States generics market value: $ billion, 2015-19
Figure 2: United States generics market volume: % of total pharma, 2015-19
Figure 3: United States generics market geography segmentation: % share, by value, 2019
Figure 4: United States generics market value forecast: $ billion, 2019-24
Figure 5: United States generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in the United States, 2019
Figure 7: Drivers of buyer power in the generics market in the United States, 2019
Figure 8: Drivers of supplier power in the generics market in the United States, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2019
Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2019


More Publications